2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Cytoskeleton
  4. PAK

PAK

p21 activated kinases

PAK

Related Products

PDF 0.04 MB

PAKs (p21-activated kinases) are a family of six serine/threonine kinases that act as key effectors of RHO family GTPases in mammalian cells. PAKs are subdivided into two groups: group I (PAK1, PAK2, and PAK3) and group II (PAK4, PAK5, and PAK6), based on their domain architecture and regulation. Group I PAKs are activated by GTPases such as Cdc42, Rac, TC10, CHP, and Wrch-1, as well as in a GTPase-independent manner. Group II PAKs are generally not activated by Cdc42/Rac binding. PAK plays important roles in cytoskeletal organization, cellular morphogenesis, and survival, and members of this family have been implicated in many diseases including cancer, infectious diseases, and neurological disorders.

PAKs participate in various signaling networks. PAKs activate the MAPK pathway by phosphorylating Raf1 in addition to NF-κB. PAKs also phosphorylate a number of regulators of the cytoskeleton such as MLCK, LIMK, filamin A, ILK, merlin, and Arpc1b. In addition, PAKs regulate survival and apoptotic pathways through phosphorylation of its effectors such as DLC1 and BimL. On translocation to the nucleus, PAKs directly affect gene transcription. Several transcription factors and transcriptional co-regulators such as FKHR, SHARP, CTBP1 and SNAI1 are substrates to PAK1. PAKs also regulate cell cycle progression through phosphorylation of histone H3, Aurora A and PlK1.

PAK Isoform Specific Products:

PAK Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS09987
    PAK2 Human Pre-designed siRNA Set A
    		Inhibitor

    PAK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PAK2 Human Pre-designed siRNA Set A
  • HY-143704S
    5-Aminosalicylic acid-13C6 hydrochloride
    		Inhibitor 99.53%
    5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
    5-Aminosalicylic acid-<sup>13</sup>C<sub>6</sub> hydrochloride
  • HY-11063S
    Fingolimod-d4
    		Activator 99.11%
    Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a brain-penetrant sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant.
    Fingolimod-d<sub>4</sub>
  • HY-11063S1
    Fingolimod-d4 hydrochloride
    		Activator 99.0%
    Fingolimod-d4 (hydrochloride) is the deuterium labeled Fingolimod hydrochloride. Fingolimod hydrochloride (FTY720) is a brain-penetrant sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride (FTY720) also is a pak1 activator, a immunosuppressant.
    Fingolimod-d<sub>4</sub> hydrochloride
  • HY-RS09992
    Pak3 Rat Pre-designed siRNA Set A
    		Inhibitor

    Pak3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Pak3 Rat Pre-designed siRNA Set A
  • HY-124398
    GL-1196
    		Inhibitor
    GL-1196 is an inhibitor of PAK4. GL-1196 can suppress the proliferation and invasion of gastric cancer cells. GL-1196 inhibits PAK4-mediated signaling pathways. GL-1196 can hinder the proliferation of human gastric cancer cells through suppressing PAK4/c-Src/EGFR/CyclinD1 and CDK4/6. GL-1196 can reduce filamentous pseudopodia formation and induce filamentous pseudopodia formation and promote cell elongation in SGC7901 and BGC823 cells. GL-1196 can be studied in anti-cancer research.
    GL-1196
  • HY-146681
    PAK1-IN-1
    		Inhibitor
    PAK1-IN-1 is a potent and selective PAK1 inhibitor with an IC50 of 9.8 nM. PAK1-IN-1 inhibits the migration and invasion of PAK1-related tumour cells in a dose-dependent manner.
    PAK1-IN-1
  • HY-RS09997
    Pak5 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Pak5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Pak5 Mouse Pre-designed siRNA Set A
  • HY-RS09989
    PAK2 Rat Pre-designed siRNA Set A
    		Inhibitor

    PAK2 Rat Pre-designed siRNA Set A contains three designed siRNAs for PAK2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PAK2 Rat Pre-designed siRNA Set A
  • HY-155179
    ZMF-23
    		Inhibitor
    ZMF-23 is a PAK1/HDAC6 dual inhibitor. ZMF-23 inhibits PAK1 and HDAC6 regulated aerobic glycolysis and migration. ZMF-23 induces TNF-α-regulated necroptosis, and further enhances apoptosis. ZMF-23 inhibits the Warburg effect and cell migration. ZMF-23 can be used for research of triple-negative breast cancer (TNBC).
    ZMF-23
  • HY-RS09998
    Pak5 Rat Pre-designed siRNA Set A
    		Inhibitor

    Pak5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Pak5 Rat Pre-designed siRNA Set A
  • HY-RS10000
    Pak6 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Pak6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Pak6 Mouse Pre-designed siRNA Set A
  • HY-15027S2
    5-Aminosalicylic acid-13C6
    5-Aminosalicylic acid-13C6 is the 13C labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
    5-Aminosalicylic acid-<sup>13</sup>C<sub>6</sub>
  • HY-183610
    WRN-IN-26
    		Inducer
    WRN-IN-26 is an orally active Werner syndrome helicase (WRN) inhibitor with a human Ki value of 58.7 μM and an IC50 value of 0.026 μM. WRN-IN-26 selectively targets the cysteine residues of WRN. WRN-IN-26 induces the expression of p21 protein in MSI-H tumor cells. WRN-IN-26 inhibits the growth of MSI-H tumor cells and exhibits potent in vivo efficacy in MSI-H xenograft tumor models. WRN-IN-26 can be used for the research of microsatellite instability-high (MSI-H) cancers.
    WRN-IN-26
  • HY-174248
    PS21M
    		Control
    PS21M is a negative control of CPS-021 (HY-174247). PS21M cannot effectively degrade PAK4 in MDA-MB-231 cells. (Pink: Target Protein Ligand (HY-174822); Black: Linker; Blue: E3 Ligase Ligand (HY-W586822)).
    PS21M
  • HY-RS09990
    PAK3 Human Pre-designed siRNA Set A
    		Inhibitor

    PAK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PAK3 Human Pre-designed siRNA Set A
  • HY-13007A
    PF-3758309 hydrochloride
    		Inhibitor
    PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation.
    PF-3758309 hydrochloride
  • HY-183246
    Rac/Cdc42-IN-1
    		Inhibitor
    Rac/Cdc42-IN-1, the major phase I metabolite of the oral Rac/Cdc42 inhibitor MBQ-167 (HY-112842) in vivo, is a selective Rac inhibitor. Rac/Cdc42-IN-1 functions by blocking the GTP-binding activation of Rac1, targeting the autophosphorylation of Thr423/Thr402/Thr436 and Ser141/Ser144/Ser154 in downstream PAK1/2/3, with an inhibitory effect superior to that of MBQ-167. Rac/Cdc42-IN-1 significantly inhibits cell migration, and suppresses tumor growth and distant metastasis to the lung, liver and kidney in HER2+ breast cancer mouse models. Rac/Cdc42-IN-1 can be used for targeted research on metastatic breast cancer.
    Rac/Cdc42-IN-1
  • HY-159897
    PAK4-IN-5
    		Inhibitor
    PAK4-IN-5 (Compound 12i) is a PAK4 inhibitor (IC50: 7.68 nM for PAK4, 1872.01 nM for PAK1). PAK4-IN-5 binds to PAK4 stably via multiple interactions. PAK4-IN-5 inhibits the proliferation and the migratory potential of MDA-MB-231 cells by inhibiting the phosphorylation of PAK4 and LIMK1. PAK4-IN-5 arrests cell cycle in the G0/G1 phase, induces apoptosis and ROS production. LD50: >500 mg/kg for mice (p.o.).
    PAK4-IN-5
  • HY-RS09993
    PAK4 Human Pre-designed siRNA Set A
    		Inhibitor

    PAK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PAK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PAK4 Human Pre-designed siRNA Set A
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
PAK Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.